Robert A. Fridell, Chunfu Wang, Jin‐Hua Sun, Donald R. O'Boyle, Peter Nower, Lourdes Valera, Dike Qiu, Susan Roberts, Xin Huang, Bernadette Kienzle, Marc Bifano, Richard E. Nettles, Min Gao – 2 December 2011 – The NS5A replication complex inhibitor, BMS‐790052, inhibits hepatitis C virus (HCV) replication with picomolar potency in preclinical assays. This potency translated in vivo to a substantial antiviral effect in a single‐ascending dose study and a 14‐day multiple‐ascending dose (MAD) monotherapy study.

Katia Bourd‐Boittin, Dominique Bonnier, Anthony Leyme, Bernard Mari, Pierre Tuffery, Michel Samson, Frédéric Ezan, Georges Baffet, Nathalie Theret – 2 December 2011

Silvia Ruiz‐Gaspà, Angels Martinez‐Ferrer, Nuria Guañabens, Marta Dubreuil, Pilar Peris, Anna Enjuanes, Maria Jesús Martinez de Osaba, Luisa Alvarez, Ana Monegal, Andrés Combalia, Albert Parés – 2 December 2011 – Low bone formation is considered to be the main feature in osteoporosis associated with cholestatic and end‐stage liver diseases, although the consequences of retained substances in chronic cholestasis on bone cells have scarcely been studied.

David Da Ines, Wassim Essamet, Pierre F. Montoriol – 2 December 2011

Sidonie K. Hartridge‐Lambert, Eytan M. Stein, Arnold J. Markowitz, Carol S. Portlock – 26 November 2011 – Hepatitis C virus (HCV) is a commonly transmitted infection that has both hepatic and extrahepatic repercussions. These range from the inflammatory to the oncologic with an undisputed link to hepatitis, liver cirrhosis, and hepatocellular carcinoma. Its role in the development of B cell non‐Hodgkin lymphoma (B‐NHL) is becoming better understood, leading to opportunities for research, therapy, and even prevention.

Anna Albecka, Sandrine Belouzard, Anne Op de Beeck, Véronique Descamps, Lucie Goueslain, Justine Bertrand‐Michel, François Tercé, Gilles Duverlie, Yves Rouillé, Jean Dubuisson – 26 November 2011 – Hepatitis C virus (HCV) particles are known to be in complex with lipoproteins. As a result of this interaction, the low‐density lipoprotein (LDL) receptor (LDLR) has been proposed as a potential entry factor for HCV; however, its implication in virus entry remains unclear.

David B. Rein, Gretchen A. Stevens, Jordan Theaker, John S. Wittenborn, Steven T. Wiersma – 26 November 2011 – We estimated the global burden of hepatitis E virus (HEV) genotypes 1 and 2 in 2005. HEV is an emergent waterborne infection that causes source‐originated epidemics of acute disease with a case fatality rate thought to vary by age and pregnancy status.

Michael H. Nathanson – 26 November 2011

Bharath Nath, Gyongyi Szabo – 26 November 2011 – Hypoxia has been shown to have a role in the pathogenesis of several forms of liver disease. The hypoxia inducible factors (HIFs) are a family of evolutionarily conserved transcriptional regulators that affect a homeostatic response to low oxygen tension and have been identified as key mediators of angiogenesis, inflammation, and metabolism. In this review we summarize the evidence for a role of HIFs across a range of hepatic pathophysiology.

Karim C. El Kasmi, Aimee L. Anderson, Michael W. Devereaux, Sophie A. Fillon, J. Kirk Harris, Mark A. Lovell, Milton J. Finegold, Ronald J. Sokol – 26 November 2011 – Infants with intestinal failure who are parenteral nutrition (PN)‐dependent may develop cholestatic liver injury and cirrhosis (PN‐associated liver injury: PNALI). The pathogenesis of PNALI remains incompletely understood.